GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RemeGen Co Ltd (OTCPK:REGMF) » Definitions » Other Stockholders Equity

REGMF (RemeGen Co) Other Stockholders Equity : $4.0 Mil (As of Jun. 2024)


View and export this data going back to 2020. Start your Free Trial

What is RemeGen Co Other Stockholders Equity?

RemeGen Co's Other Stockholders Equity for the quarter that ended in Jun. 2024 was $4.0 Mil.

RemeGen Co's quarterly Other Stockholders Equity declined from Jun. 2023 ($4.5 Mil) to Dec. 2023 ($3.6 Mil) but then increased from Dec. 2023 ($3.6 Mil) to Jun. 2024 ($4.0 Mil).

RemeGen Co's annual Other Stockholders Equity declined from Dec. 2021 ($534.7 Mil) to Dec. 2022 ($11.5 Mil) and declined from Dec. 2022 ($11.5 Mil) to Dec. 2023 ($3.6 Mil).


RemeGen Co Other Stockholders Equity Historical Data

The historical data trend for RemeGen Co's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RemeGen Co Other Stockholders Equity Chart

RemeGen Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Other Stockholders Equity
Get a 7-Day Free Trial 474.79 534.71 11.55 3.64 259.21

RemeGen Co Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.55 4.53 3.64 4.01 259.21

RemeGen Co Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity


RemeGen Co Other Stockholders Equity Related Terms

Thank you for viewing the detailed overview of RemeGen Co's Other Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


RemeGen Co Business Description

Traded in Other Exchanges
Address
58 Middle Beijing Road, Yantai Area of Shandong Pilot Free Trade Zone, Yantai Development Zone, Yantai, CHN
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of innovative biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat major diseases such as autoimmune diseases, oncology, and ophthalmology. The company has its operations in China and the USA and derives the majority of its revenue from China.

RemeGen Co Headlines

From GuruFocus